Guardant Health
Financials
Estimates*
| USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenues | 287m | 374m | 450m | 564m | 695m | 824m | 993m |
| % growth | 34 % | 30 % | 20 % | 25 % | 23 % | 19 % | 21 % |
| EBITDA | (241m) | (382m) | (651m) | (433m) | (293m) | (271m) | (317m) |
| % EBITDA margin | (84 %) | (102 %) | (145 %) | (77 %) | (42 %) | (33 %) | (32 %) |
| Profit | (254m) | (406m) | (655m) | (479m) | (390m) | (343m) | (283m) |
| % profit margin | (89 %) | (109 %) | (146 %) | (85 %) | (56 %) | (42 %) | (29 %) |
| EV / revenue | 41.5x | 27.8x | 6.5x | 5.8x | 5.0x | 4.5x | 3.9x |
| EV / EBITDA | -49.3x | -27.1x | -4.5x | -7.5x | -11.8x | -13.5x | -12.1x |
| R&D budget | 150m | 263m | 374m | 367m | - | - | - |
| R&D % of revenue | 52 % | 70 % | 83 % | 65 % | - | - | - |
Source: Dealroom estimates
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
N/A | Convertible | ||
$10.0m | Series A | ||
$30.0m | Series B | ||
$50.0m | Series C | ||
$100m | Series D | ||
$360m | Series E | ||
| N/A | $238m Valuation: $1.6b 32.1x EV/LTM Revenues -21.2x EV/LTM EBITDA | IPO | |
* | N/A | $1.0b | Post IPO Convertible |
* | N/A | $350m | Post IPO Equity |
* | $288k | Post IPO Equity | |
| Total Funding | €500m | ||
Related Content
Recent News about Guardant Health
EditGuardant Health is a pioneering company in the field of oncology, specializing in blood-based tests that provide critical data for cancer treatment and management. The company serves patients at all stages of cancer, from early detection to advanced disease management. Operating in the healthcare and biotechnology markets, Guardant Health's business model revolves around developing and selling diagnostic tests that leverage the power of blood samples to detect, monitor, and guide treatment decisions for cancer patients. Revenue is primarily generated through the sale of these tests to healthcare providers, hospitals, and research institutions. The company's flagship product, Guardant360, is FDA-approved and widely used to inform treatment decisions for patients with advanced cancer. Additionally, Guardant Health is expanding its portfolio to include tests for early-stage cancer detection and recurrence monitoring. By focusing on non-invasive, data-rich diagnostics, Guardant Health aims to improve patient outcomes and reduce the overall burden of cancer.
Keywords: oncology, blood tests, cancer detection, advanced cancer, early-stage cancer, diagnostics, FDA-approved, healthcare, biotechnology, data-driven.
